Cargando…

A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients’ Omics Signatures

SIMPLE SUMMARY: Current therapies for bladder cancer present limitations as, regularly, not all patients benefit from treatment. Drug repurposing refers to the use of available drugs in new disease contexts. In this study, we identified drugs of potential to be repurposed, e.g., used in the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mokou, Marika, Lygirou, Vasiliki, Angelioudaki, Ioanna, Paschalidis, Nikolaos, Stroggilos, Rafael, Frantzi, Maria, Latosinska, Agnieszka, Bamias, Aristotelis, Hoffmann, Michèle J., Mischak, Harald, Vlahou, Antonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759896/ https://www.ncbi.nlm.nih.gov/pubmed/33255925 http://dx.doi.org/10.3390/cancers12123519

Ejemplares similares

Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention
por: Latosinska, Agnieszka, et al.
Publicado: (2017)

Gene Expression Monotonicity across Bladder Cancer Stages Informs on the Molecular Pathogenesis and Identifies a Prognostic Eight-Gene Signature
por: Stroggilos, Rafael, et al.
Publicado: (2022)

Urine peptidome analysis in cardiorenal syndrome reflects molecular processes
por: Petra, Eleni, et al.
Publicado: (2021)

Proteomic Analysis of Prostate Cancer FFPE Samples Reveals Markers of Disease Progression and Aggressiveness
por: Lygirou, Vasiliki, et al.
Publicado: (2022)

Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca(2+) signaling in T24M-based bladder cancer models
por: Frantzi, Maria, et al.
Publicado: (2016)

BcCluster: A Bladder Cancer Database at the Molecular Level
por: Bhat, Akshay, et al.
Publicado: (2016)

Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of –omics findings
por: Latosinska, Agnieszka, et al.
Publicado: (2016)

Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination
por: Frantzi, Maria, et al.
Publicado: (2023)

Multiplexed MRM-based protein quantification of putative prognostic biomarkers for chronic kidney disease progression in plasma
por: Makridakis, Manousos, et al.
Publicado: (2020)

Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease
por: Lygirou, Vasiliki, et al.
Publicado: (2018)

Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation
por: Latosinska, Agnieszka, et al.
Publicado: (2020)

Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer
por: Frantzi, Maria, et al.
Publicado: (2020)

Urinary CE-MS peptide marker pattern for detection of solid tumors
por: Belczacka, Iwona, et al.
Publicado: (2018)

Author Correction: Urinary CE-MS peptide marker pattern for detection of solid tumors
por: Belczacka, Iwona, et al.
Publicado: (2019)

Urinary peptides provide information about the risk of mortality across a spectrum of diseases and scenarios
por: Keller, Felix, et al.
Publicado: (2023)

Analytical Performance of ELISA Assays in Urine: One More Bottleneck towards Biomarker Validation and Clinical Implementation
por: Chatziharalambous, Despina, et al.
Publicado: (2016)

Promise and Implementation of Proteomic Prostate Cancer Biomarkers
por: Latosinska, Agnieszka, et al.
Publicado: (2018)

Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions
por: Frantzi, Maria, et al.
Publicado: (2017)

Urinary peptide panel for prognostic assessment of bladder cancer relapse
por: Krochmal, Magdalena, et al.
Publicado: (2019)

Glycosylation Analysis of Urinary Peptidome Highlights IGF2 Glycopeptides in Association with CKD
por: Lohia, Sonnal, et al.
Publicado: (2023)

Comparison of Depletion Strategies for the Enrichment of Low-Abundance Proteins in Urine
por: Filip, Szymon, et al.
Publicado: (2015)

Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease
por: Mokou, Marika, et al.
Publicado: (2019)

Collagen-Derived Peptides in CKD: A Link to Fibrosis
por: Mavrogeorgis, Emmanouil, et al.
Publicado: (2021)

Proteomic Analysis of Mouse Kidney Tissue Associates Peroxisomal Dysfunction with Early Diabetic Kidney Disease
por: Tserga, Aggeliki, et al.
Publicado: (2022)

Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer
por: Frantzi, Maria, et al.
Publicado: (2022)

Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis
por: Krochmal, Magdalena, et al.
Publicado: (2017)

Molecular Mapping of Urinary Complement Peptides in Kidney Diseases
por: Wendt, Ralph, et al.
Publicado: (2021)

Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development
por: Frantzi, Maria, et al.
Publicado: (2014)

Plasma Proteomics in Healthy Subjects with Differences in Tissue Glucocorticoid Sensitivity Identifies A Novel Proteomic Signature
por: Nicolaides, Nicolas C., et al.
Publicado: (2022)

Functional secretome analysis reveals Annexin-A1 as important paracrine factor derived from fetal mesenchymal stem cells in hepatic regeneration
por: Zagoura, Dimitra, et al.
Publicado: (2019)

Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma
por: Voigtländer, Torsten, et al.
Publicado: (2020)

A Model to Detect Significant Prostate Cancer Integrating Urinary Peptide and Extracellular Vesicle RNA Data
por: O’Connell, Shea P., et al.
Publicado: (2022)

Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis
por: Latosinska, Agnieszka, et al.
Publicado: (2015)

Microbiome in Chronic Kidney Disease (CKD): An Omics Perspective
por: Lohia, Sonnal, et al.
Publicado: (2022)

Urinary peptidomic profiles to address age-related disabilities: a prospective population study
por: Martens, Dries S, et al.
Publicado: (2021)

Reviewing the Regulators of COL1A1
por: Devos, Hanne, et al.
Publicado: (2023)

The New Age of -omics in Urothelial Cancer – Re-wording Its Diagnosis and Treatment
por: Katsila, Theodora, et al.
Publicado: (2018)

CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
por: Frantzi, Maria, et al.
Publicado: (2019)

Repurposed agents in the Alzheimer’s disease drug development pipeline
por: Bauzon, Justin, et al.
Publicado: (2020)

A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI
por: Husi, Holger, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gf2p1bicfvhgut3i0du3h4v3mk